Kolkata shows better control on Diabetes in India: RWE study

IMT News Desk
IMT News Desk
· 3 min read
diabetes

New Delhi, April 2019: Diabetes patients in Kolkata (East region) and Mumbai (West region) showed a slightly better control among the four selected cities representing different regions in India- with an average Haemoglobin A1c (often abbreviated as HbA1c) control of 8.35% and 8.46% respectively versus 8.56% in Chennai (South region) and 8.77% in Delhi (North region) in a Real World Evidence backed study by THB (Technology, Healthcare & Bigdata Analytics).

The study cites that~4 out of 10 diabetic patients in Delhi are living with a poor HbA1c level of more than 10%. The ADA (American Diabetes Association) guidelines recommend a target of 7% for the general population and the ICSI (Institute for Clinical Systems Improvement) guideline recommends less than 7% to less than 8% based on different patient factors).

These findings basis RWE also resonate the findings of ICMR-INDIAB study which showed that out of the four regions studied the prevalence of diabetes was highest in Chandigarh from the northern region. Highly sedentary lifestyle of the residents in the North, followed by South, West, and East was highlighted as a possible explanation (Lancet, 2017).

While there could be multiple factors driving nuances behind poor diabetes control, e.g. degree of compliance, prescription patterns, lifestyle, etc., further analysis was needed to understand the patient behaviour, and degree of compliance in these four cities from different Indian regions.

For patients with Diabetes, regular check-ups and doctor consultations can help improve their quality of life, as a tighter watch can make one aware and diligent towards their own health and, for healthcare practitioners and pharmaceutical companies- keeping track of the real state of Diabetes in India can help them put forward the right cognizance tactics in motivating the patients to follow their routine suggestive treatment. In this regard, THB, India’s leading clinical intelligence company delivering personalized care and syndicated insights, further investigated with the help of its proprietary big datasets on Indian population to derive possible reasoning behind the poor control in the country.

The analysis revealed that the percentage of patients with Diabetes revisiting healthcare providers within a period of 6 months were 36% in Delhi (Northern region), 33% in Mumbai (Western region), 27% in Chennai (Southern region) and 35% in Kolkata (Eastern region), which clearly portrayed the poor HbA1C performance in all these regions. Surprisingly, Chennai patients showed a unique behaviour- While 73% of the diabetes patients revisit a healthcare service provider after more than 6 months, they get themselves monitored comprehensively (not only diabetes markers but also screening for dyslipidaemia and/or chronic kidney disease) more often than northern and eastern regions. Not necessarily leading to the best outcomes, but that’s the preference observed.

Delhi had the lowest percentage of patients who got themselves monitored comprehensively (Diabetes parameters along with other essential health parameters). This probably explains the reason behind the worst ‘degree of diabetes control’ in the city representing Northern region.

The findings have come out from an RWE analysis from out of over 3.5 Lac diabetes patients in India including four cities representing four different regions-Delhi / NCR (North), Kolkata (East), Mumbai (West) and Chennai (South).

Read Next

MedGenome makes a majority investment in Siddhi Diagnostics & Research Centre  
News
May 20, 2026

MedGenome makes a majority investment in Siddhi Diagnostics & Research Centre  

MedGenome has joined hands with Siddhi Diagnostics & Research Centre (SDRC), a well-established diagnostic imaging service provider with a strong presence across Mumbai’s extended western suburbs. Founded in 1995, SDRC is led by Dr. Ajit Pungavkar and Dr. Sona Pungavkar. Dr. Ajit, a renowned sonologist with over 35 years of clinical experience, has devoted his […]
Article by: IMT News Desk
Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
News
May 20, 2026

Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution

Global pharma major, Lupin Limited (Lupin), has announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials. Lupin’s Revefenacin Inhalation Solution, 175 mcg/3 mL is bioequivalent to Mylan’s Yupelri® Inhalation Solution and indicated for […]
Article by: IMT News Desk
HCG opens new 132‑bed Bengaluru oncology facility with ₹129 crore investment
News
May 20, 2026

HCG opens new 132‑bed Bengaluru oncology facility with ₹129 crore investment

HealthCare Global Enterprises (HCG) has inaugurated a new 132‑bed comprehensive cancer care hospital in Hebbal/North Bengaluru, marking its third oncology facility in the city and expanding its network across Karnataka and India. Scale and investment The new Bengaluru facility represents a total investment of approximately ₹129 crore, funded through a mix of debt and internal […]
Article by: IMT News Desk
Hidden sugar patterns on the cell surface could enable early cancer detection, a new study shows
News
May 20, 2026

Hidden sugar patterns on the cell surface could enable early cancer detection, a new study shows

Scientists have uncovered a hidden “sugar code” on the surface of human cells that could revolutionize early‑stage cancer diagnosis, according to a new study published in Nature Nanotechnology by researchers at the Max Planck Institute for the Science of Light (MPL). What the study found Every human cell is coated with a thin layer of sugar molecules […]
Article by: IMT News Desk